CM
CMMB.US Chemomab Therapeutics Ltd DRC
- Market cap
- USD 12.3M
- P/E
- -
- P/B
- 1.31x
- ROE
- -91.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CMMB.US undervalued?
Graham numberThe Graham number of Chemomab Therapeutics Ltd DRC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chemomab Therapeutics Ltd DRC fundamental analysis
No fundamental analysis for Chemomab Therapeutics Ltd DRC yet.
Chemomab Therapeutics Ltd DRC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical t…
Full company profileChemomab Therapeutics Ltd DRC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chemomab Therapeutics Ltd DRC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -40.6K | -51.0K | -66.0K | -281K | -80.6K | -34.0K | -57.8K | -66.8K | -53.3K | -70.6K | - |
| Operating Income | -4.63M | -9.39M | 12.7M | 27.1M | -11.0M | -12.4M | -28.5M | -25.5M | -14.7M | -9.57M | -8.26M |
| EBITDA | -4.57M | -9.50M | 12.7M | 27.1M | -11.0M | -12.3M | -28.5M | -25.4M | -14.7M | -9.50M | -8.22M |
| Net Income | -4.73M | -9.81M | 13.3M | 27.1M | -11.7M | -12.5M | -27.6M | -24.2M | -13.9M | -9.00M | -7.95M |
| EPS | -70 | -869 | 84 | 63 | -504 | -4.81 | -9.72 | -8.25 | -69 | -1.41 | -0.99 |
| Balance Sheet | |||||||||||
| Total Assets | 5.65M | 2.09M | 12.8M | 19.8M | 12.5M | 64.4M | 43.1M | 22.2M | 17.0M | 13.8M | 10.2M |
| Total Liabilities | 2.36M | 2.70M | 2.96M | 4.85M | 1.67M | 2.89M | 6.84M | 5.15M | 3.43M | 1.48M | 1.55M |
| Shareholders' Equity | 3.29M | -609K | 9.81M | 12.4M | 10.8M | 61.5M | 36.2M | 17.0M | 13.5M | 12.3M | 8.68M |
| Cash & Short-term Investments | 4.56M | 1.45M | 7.52M | 17.6M | 11.7M | 61.2M | 39.9M | 19.8M | 14.3M | 10.4M | 6.69M |
| Total Debt | - | - | - | 586K | 607K | 343K | 214K | 392K | 324K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.74M | -8.58M | -14.2M | -16.5M | -12.8M | -12.4M | -20.3M | -23.6M | -15.5M | -11.2M | - |
| Capital Expenditure | 76.1K | 34.3K | 212K | 95.3K | 34.2K | 239K | 67.7K | 2.99K | 4.96 | 3.03K | 0.00 |
| Free Cash Flow | -3.81M | -8.62M | -14.4M | -16.6M | -12.8M | -12.6M | -20.4M | -23.6M | -15.5M | -11.2M | - |
| Ratios | |||||||||||
| ROE | -143.7% | - | 135.4% | 219.2% | -108.2% | -20.3% | -76.3% | -142.5% | -103.0% | -72.9% | -91.5% |
| ROA | -83.8% | -469.9% | 104.1% | 137.3% | -93.7% | -19.4% | -64.2% | -109.3% | -82.2% | -65.1% | -77.7% |
| Debt to Equity | - | - | - | 0.05x | 0.06x | 0.01x | 0.01x | 0.02x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chemomab Therapeutics Ltd DRC dividends
Chemomab Therapeutics Ltd DRC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Aug 26, 2025.
Who owns Chemomab Therapeutics Ltd DRC
- Insiders 6.57%
- Institutions 20.52%
- Public & others 72.91%
- Shares outstanding 8.05M
- Free float 5.05M
Top funds holding CMMB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 1.01M | 9.46% | +344.90% | Sep 2026 |
Top institutions holding CMMB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Advisory Services Network, LLC | 0.00 | 0.00% | -100.00% | Mar 2024 |
Chemomab Therapeutics Ltd DRC company profile
- Company name
- Chemomab Therapeutics Ltd DRC
- Ticker
- CMMB.US
- Exchange
- USA Stocks
- Listed since
- Feb 12, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Building C, Tel Aviv-Yafo, Israel, 6158101
- Phone
- 972 77 331 0156
- Website
- chemomab.com
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Chemomab Therapeutics Ltd DRC management
5- Dr. Adi Mor George Ph.D.Co-Founder, Chief Scientific Officer, CEO & Executive Director · born 1982
- Ms. Sigal Fattal CPA, M.B.A.Chief Financial Officer · born 1971
- Mr. John LawlerChief Development Officer
- Ms. Barbara L. LindheimConsulting Vice President of Investor & Public Relations, Strategic Communications · born 1950
- Dr. David M. Weiner M.B.A., M.D.Interim Chief Medical Officer · born 1965